Search

1. Outline an innovative model for integrating pharmacist-led patient care into a palliative care clinic. 2. Review two patient-centered outcomes that are improved by a pharmacist-led clinic and highlight clinical characteristics of patients who benefit from pharmacy involvement. Pharmacists play several roles within the outpatient palliative care setting, and their involvement in patient care is associated with improved patient safety and clinical outcomes. At Dana-Farber Cancer Institute, pharmacists have participated in co-visits with the primary palliative care clinician since 2001, and in July of 2020, a collaborative drug therapy management clinic, "PharmPAL," was piloted. PharmPAL clinic allows credentialed pharmacists to lead follow-up palliative care visits encompassing patient assessments, counseling, education, ordering of laboratory tests, and prescribing and managing medication regimens. The goal of PharmPAL is to increase access to palliative care by expanding the availability of follow-up care to patients with intense symptom management needs. Primary reasons for PharmPAL referral include new consult requiring close follow-up, education and counseling, stable patient for refill review, schedule availability, and patients with recent or anticipated medication changes. PharmPAL volume has grown from 24 visits in its first quarter of operation to 96 visits in the most recent quarter. We have increased pharmacist availability to support this growth and have plans for further expansion with a third pharmacist joining PharmPAL clinic in 2023. Surveys have confirmed clinician satisfaction with the various models of pharmacist support, and we continue to use feedback to plan pharmacist involvement within the palliative care clinic and PharmPAL. The increase of patient encounters in the pharmacist-led clinic has aligned with a concomitant increase in outpatient clinic volume overall. In this session we will share data around the implementation and growth of this model as well as lessons learned and practical tips around developing a similar model in your own setting. We will further describe two case examples of oncology patients managed in the PharmPAL clinic to demonstrate the comanagement between the pharmacists, oncologists, and palliative care clinicians as well as give examples of patient-related outcomes. [ABSTRACT FROM AUTHOR]

1. Review the roles of palliative care pharmacists in the outpatient clinic setting 2. Summarize current practice models in the outpatient palliative care setting 3. Outline the development of PharmPAL and overall clinic metrics Pharmacists play several roles in the outpatient palliative care setting, and their involvement in patient care is associated with improved patient safety and clinical outcomes. At Dana-Farber we have two primary ways that our embedded palliative care pharmacists are involved in clinical care. Pharmacists have participated in co-visits with the primary clinician since 2001, primarily providing suggestions about medication management. In July 2020 a collaborative drug therapy management clinic called PharmPAL was piloted. PharmPAL allows credentialed pharmacists to lead follow-up palliative care visits encompassing patient assessments, counseling, education, ordering of laboratory tests, and prescribing and management of medication regimens. The goal of PharmPAL is to support the palliative care clinic by increasing the availability of follow-up care to patients with intensive symptom management needs. We aimed to determine whether clinicians were satisfied with this pilot or whether it hindered interdisciplinary care by decreasing pharmacist availability for co-visits. Surveys were disseminated to assess clinician satisfaction with the various models of pharmacist support, and we used that feedback to plan future pharmacist support of the palliative care clinic. Primary reasons for PharmPAL referral included new consult requiring close follow-up, education, and counseling, stable patient for refill review, schedule availability, and patients with recent or anticipated medication changes. The main barriers to using PharmPAL involved pharmacist availability. Based on an overwhelming percentage of providers in favor of increasing PharmPAL visits, the weekly availability increased from eight 30-minute appointments per week to twelve 30-minute appointments each week. Increased PharmPAL availability led to a 38% increase in patient encounters in the PharmPAL clinic and an increase in outpatient clinic volume overall. Additional surveys are used to address feedback for ongoing areas for improvement to continue increasing PharmPAL referrals and maintain overall provider satisfaction with pharmacy involvement. [ABSTRACT FROM AUTHOR]

Context: Entrustable professional activities (EPAs) translate competencies into explicit, practical terms that clearly state the expected roles and responsibilities of clinicians who have achieved proficiency and expertise in a field. EPAs are defined for Hospice and Palliative Medicine physicians but not for other members of Hospice and Palliative Care (HAPC) interprofessional teams, including pharmacists.Objectives: The objective of this study was to develop EPAs for HAPC pharmacists.Methods: An 11-member workgroup of HAPC pharmacists was convened to develop candidate EPAs using nominal group and modified-Delphi methods. Content validity index was used as a measure of consensus, defined a priori at ≥ 60%. Vetting occurred via intra- and interprofessional stakeholder reactor groups and a national survey of HAPC pharmacists.Results: Following an iterative process of workgroup and stakeholder consensus-building, 15 HAPC pharmacist EPAs were developed. Among the workgroup, all 15 EPAs reached ≥ 70% consensus, indicating appropriate internal validity. In a national survey of 185 HAPC pharmacists with a 20% response rate, 13 EPAs were rated by most respondents as "essential" and 2 were rated by most respondents as "important but not essential." Respondents indicated the 15 EPA set represented the core professional activities of HAPC pharmacists well (median rating of 5 on a Likert-like scale, IQR 1).Conclusion: Fifteen consensus EPAs describe essential activities of HAPC pharmacists in direct patient care, leadership, education, and scholarship. These EPAs will further guide pharmacist training programs, HAPC services seeking to incorporate a specialized pharmacist on the team, and currently practicing HAPC pharmacists. [ABSTRACT FROM AUTHOR]

1. Identify candidates for topical morphine use in pain refractory to other analgesics and opioids. 2. Describe evidence behind use of morphine gel in palliative care and barriers to use in a practical setting. Opioids are a mainstay of treatment for moderate to severe cancer-related pain. Conventional opioids act on opioid receptors in the central nervous system; however, opioid receptors are also present in the skin, providing an opportunity for their use as a topical analgesic when there is skin breakdown and potentially limiting systemic side effects. Topical morphine has demonstrated effective pain relief in palliative care patients, but its use is uncommon and evidence is limited. As a result, it is not widely available or affordable. Ms. B is a 76-year-old female with a history of recurrent lung adenocarcinoma for which she underwent radiotherapy targeting a left lower lobe mass. After radiation she began to develop skin erosions on her back that caused significant pain and greatly reduced her functionality and independence. She was referred to the outpatient palliative care clinic after seeing multiple other specialists. She had previous trials of acetaminophen, gabapentin (oral and topical), lidocaine (patch and ointment), oxycodone, and intralesional anesthetics, which were all ineffective or resulted in intolerable adverse effects. Due to the size and nature of her lesions, she was a candidate for trial of topical morphine gel. Many logistical barriers were encountered, including availability and cost to the patient from a compounding pharmacy. She reported significant relief at her next visit with palliative care but expressed anxiety regarding whether she would be able to continue to afford it. Studies show topical morphine effectively provides local analgesia in palliative care patients without producing systemic effects, but sample sizes are limited and its use is still rare. This presentation will discuss topical morphine's place in therapy and appropriate patients for its use, as well as highlight the primary barriers to its use including out-of-pocket cost to patients from lack of coverage by most prescription insurance plans. [ABSTRACT FROM AUTHOR]